NRTC-103

Rosa Canina, Urtica Dioica, Tanacetum Vulgare Herbal Extract Capsules

NRTC-103 Bottle Photo
  • Formulated to match Neurotec
  • 100 mg dried extracts per capsule
  • Thujone-free
  • 180 capsules (90 day supply)
  • Now available in the United States and sold as a dietary supplement
Order now

NRTC-103™ is a U.S.-manufactured dietary supplement designed to faithfully replicate the original Neurotec multi-herbal capsule formulation studied in placebo-controlled clinical trials and described in peer-reviewed scientific literature. It contains the same three dried herbal extracts—Rosa canina, Urtica dioica, and Tanacetum vulgare—in the exact same amounts, and is standardized to match the original manufacturer’s chemical specifications and identifying characteristics, making it interchangeable and comparable to Neurotec in every meaningful, measurable way.

Until recently, Neurotec had no substitutes and was not legally accessible outside its country of origin due to export restrictions, despite growing international interest driven by the published research. In late 2024, an FDA-registered manufacturing facility in Colorado (TG Labs Inc.) began producing NRTC-103 to make this formulation domestically available in the United States.

NRTC-103 is sold as a non-official replication of Neurotec, intended solely as a dietary supplement and presented without disease or treatment claims; it is not intended to diagnose, treat, prevent, or cure any disease, and should be used only in a manner consistent with its definition as a dietary supplement.

-

-

-

As seen in the research

-

Label

MANUFACTURED BY TG LABS INC FOR:
URGENT RESEARCH LLC
7207 N SHADELAND AVE SUITE C
INDIANAPOLIS, IN 46250, USA

Safety

Testing

  • Microbiological CoA
  • Heavy metals CoA
  • Herbal ingredients
  • Purity, potency, identity

Ingredient Interactions

  • Rosa canina L.
  • Urtica dioica L.
  • Tanacetum vulgare L.

Allergens

  • Milk

Safety & Side Effects

  • TBD

Quality Control

List of CoAs

Pricing

  • All pricing information and dollar amounts are in U.S. dollars (unless otherwise specified).
  • Product price includes shipping and handling and tax is included on all U.S. orders.
  • NRTC-103 price: $180.00 per bottle of 180 capsules.
  • Equal to approximately $1.00 per capsule (serving) or $2.00 per day (if following twice daily or suggested use).
  • Available to order exclusively through this official NRTC-103 website (nrtc103.com) and not sold elsewhere or for a lower price.
  • This product has no applicable coupon codes, no special discounts, no limited-time offers or seasonal pricing, no bulk or volume discounts, and no subscribe-and-save options.
  • Not authorized for resale.
  • Not available on third party websites or retailers.
  • All domestic orders sent within the United States include free shipping and handling.
  • Purchases backed by a 3-month 100% guarantee for qualifying returns of sealed (unopened) product.

References

MH, Atefi A, Mehri A, et al. Therapeutic effects of Rosa canina, Urtica dioica and Tanacetum vulgare herbal combination in treatment of tinnitus symptoms: A double-blind randomised clinical trial. Clin Otolaryngol. 2023;48(2):151-157. doi:10.1111/coa.13989

Li P, Che C, Wu Y, Sun S. Pharmacotherapy options for the management of subjective tinnitus: a systematic review and network meta-analysis. BMJ Open. 2025;15(5):e096995. Published 2025 May 28. doi:10.1136/bmjopen-2024-096995

Kim SH, Kim I, Kim H. Easing the Burden of Tinnitus: A Narrative Review for Exploring Effective Pharmacological Strategies. Cureus. 2024;16(2):e54861. Published 2024 Feb 25. doi:10.7759/cureus.54861

Semwal P, Rauf A, Olatunde A, et al. The medicinal chemistry of Urtica dioica L.: from preliminary evidence to clinical studies supporting its neuroprotective activity. Nat Prod Bioprospect. 2023;13(1):16. Published 2023 May 12. doi:10.1007/s13659-023-00380-5

Sherlock LP, Ballard-Hernandez J, Boudin-George A, et al. Clinical Practice Guideline for Management of Tinnitus: Recommendations From the US VA/DOD Clinical Practice Guideline Work Group. JAMA Otolaryngol Head Neck Surg. 2025;151(5):513-520. doi:10.1001/jamaoto.2025.0052

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

NRTC-103™ is a trademark owned by Urgent Research LLC.

Copyright © Urgent Research LLC. All rights reserved.